Trials / Unknown
UnknownNCT05895864
Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma
Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma After Prior Chemotherapy: a Open-label, Multicenter Phase II Study (UTRUST)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a open-label, multicenter, phase II study to evaluate the efficacy and safety of utidelone in the recurrent or metastatic urothelial carcinoma after prior chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | utidelone injection | utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone |
Timeline
- Start date
- 2023-06-07
- Primary completion
- 2024-12-31
- Completion
- 2025-12-13
- First posted
- 2023-06-09
- Last updated
- 2023-06-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05895864. Inclusion in this directory is not an endorsement.